# EDGAR Filing Document

**Accession Number:** 0001448698
**File Stem:** 0001104659-25-058646
**Filing Date:** 2025-6
**Character Count:** 10336
**Document Hash:** 7001d3e9f32d9969b87ecbc292f7fa7a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-058646.hdr.sgml**: 20250611

**ACCESSION NUMBER**: 0001104659-25-058646

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250611

**DATE AS OF CHANGE**: 20250611

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ernexa Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0000748592
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 311103425
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-42217
- **FILM NUMBER:** 251041431

**BUSINESS ADDRESS:**
- **STREET 1:** 1035 CAMBRIDGE STREET
- **STREET 2:** SUITE 18A
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02141
- **BUSINESS PHONE:** (617) 798-6700

**MAIL ADDRESS:**
- **STREET 1:** 10531 4S COMMONS DRIVE
- **STREET 2:** SUITE 166-550
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92127

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Eterna Therapeutics Inc.
- **DATE OF NAME CHANGE:** 20221017

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Brooklyn ImmunoTherapeutics, Inc.
- **DATE OF NAME CHANGE:** 20210325

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NTN BUZZTIME INC
- **DATE OF NAME CHANGE:** 20051230
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Cherington Charles
- **CENTRAL INDEX KEY:** 0001448698

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**MAIL ADDRESS:**
- **STREET 1:** ONE BOW STREET
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02138

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 7)**

**Ernexa Therapeutics Inc.**

*(Name of Issuer)*

**Common Stock, par value $0.005 per share**

*(Title of Class of Securities)*

**114082209**

*(CUSIP Number)*

**Charles Cherington**<br>c/o Ara Partners, LLC<br>200 Berkeley Street, 26th Floor<br>Boston MA 02116<br>(617) 838-3053

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**06/09/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **114082209** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Charles Cherington** | Name of reporting person<br>**Charles Cherington** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**41690775.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**41690775.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**41690775.00** | Aggregate amount beneficially owned by each reporting person<br>**41690775.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**37.9%** | Percent of class represented by amount in Row (11)<br>**37.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** Rows 7, 9 and 11 consist of (i) 41,659,743 shares of common stock, par value $0.005 per share (the "Common Stock"), of Ernexa Therapeutics Inc. (the "Issuer") and (ii) 31,032 shares of Common Stock issuable upon conversion of 71,306 shares of Series A convertible preferred stock (the "Series A Preferred Stock") of the Issuer (assuming a conversion rate of 2.2978).

Row 13 is calculated based on an aggregate 110,128,860 of shares of Common Stock of the Issuer outstanding, which is calculated by adding (i) 62,363,763 shares of Common Stock of the Issuer outstanding as of May 7, 2025 as reported on the Issuer's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 filed with the SEC on May 7, 2025,  (ii) 47,717,087 shares of Common Stock of the Issuer issued in connection with the Second Closing (as defined below) as reported on the Issuer's Current Report on Form 8-K filed with the SEC on June 9, 2025, (iii) 16,978 shares of Common Stock of the Issuer issued to the Reporting Person on June 2, 2025 as payment of a semi-annual dividend on 71,306 shares of Series A Preferred Stock and (iv) 31,032 shares of Common Stock issuable upon conversion of 71,306 shares of Series A Preferred Stock within 60 days, which are deemed outstanding pursuant to Rule 13-3(d)(1)(i).

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.005 per share

**(b) Name of Issuer:**
Ernexa Therapeutics Inc.

**(c) Address of Issuer's Principal Executive Offices:**
1035 Cambridge Street, Suite 18A, Cambridge, MA, 02141

Pursuant to Rule 13d-2 promulgated under the Securities Exchange Act of 1934, as amended, this Amendment No. 7 to Schedule 13D (this "Amendment No. 7") amends certain Items of the Schedule 13D originally filed with the SEC on May 13, 2021 (the "Original Schedule 13D"), as amended by Amendment No. 1 thereto filed with the SEC on March 16, 2022 ("Amendment No. 1"), Amendment No. 2 thereto filed with the SEC on December 14, 2022 ("Amendment No. 2"), Amendment No. 3 thereto filed with the SEC on September 7, 2023 ("Amendment No. 3"), Amendment No. 4 thereto filed with the SEC on December 20, 2023 ("Amendment No. 4"), Amendment No. 5 thereto filed with the SEC on March 5, 2025 ("Amendment No. 5"), Amendment No. 6 thereto filed with the SEC on April 4, 2025 ("Amendment No. 6," and the Original Schedule 13D, as amended by Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4, Amendment No. 5, Amendment No, 6 and this Amendment No. 7 are collectively referred to herein as the "Schedule 13D") by furnishing the information set forth below. Except as set forth below, all previous Items are unchanged.

**Item 4. Purpose of Transaction**

Item 4 is hereby amended by adding the following:  The Reporting Person acquired 21,241,163 shares of the Issuer's common stock in the Second Closing (as defined below) and 16,978 shares of the Issuer's common stock as payment-in-kind of a semi-annual dividend on shares of the Issuer's Series A Preferred Stock held by the Reporting Person paid on June 2, 2025.  The Reporting Person has no present plan or proposal that relates to, or could result in, any of the events referred to in paragraphs (a) through (j) inclusive, of Item 4 of Schedule 13D.

**Item 5. Interest in Securities of the Issuer**

**(a)**
As of June 9, 2025, the Reporting Person owns directly (i) 41,659,743 shares of Common Stock of the Issuer and (ii) 31,032 shares of Common Stock issuable upon conversion of 71,306 shares of Series A Preferred Stock of the Issuer (assuming a conversion rate of 2.2978). Rows 7, 9 and 11 set forth on the cover page to this Amendment No. 7 are hereby incorporated by reference in this Item 5(a).

**(b)**
Rows 7 through 10, inclusive, set forth on the cover page to this Amendment No. 7 are hereby incorporated by reference in this Item 5(b).

**(c)**
On June 2, 2025, the Issuer paid a dividend to all holders of record of its Series A Preferred Stock on such date of $0.05 per share of Series A Preferred Stock. Pursuant to the terms of the Series A Preferred Stock, the Issuer elected to pay the dividend in an equivalent amount of common stock. As a result, the Reporting Person received 16,978 shares of the Issuer's Common Stock as payment of the dividend on 71,306 shares of the Issuer's Series A Preferred Stock.

Pursuant to the terms of a securities purchase agreement (the "Purchase Agreement") dated as of April 2, 2025 between the Issuer and certain accredited investors, including the Reporting Person, the Issuer agreed to issue and sell to such accredited investors in a private placement an aggregate of 69,311,654 shares of Common Stock (or pre-funded warrants to purchase shares of common stock in lieu thereof) at a purchase price of $0.1046 per share. For purposes of complying with Listing Rules 5635(b) and 5635(d) of the Nasdaq Stock Market LLC, the private placement took place in two separate closings. The first closing took place on April 2, 2025.  The second closing under the Purchase Agreement (the "Second Closing") was subject to, in addition to customary conditions, stockholder approval for such issuance as required by the aforementioned Listing Rules of the Nasdaq Stock Market, LLC, which was obtained at the Issuer's 2025 Annual Meeting of Stockholders held on June 2, 2025. The Second Closing occurred on June 9, 2025 and in the Second Closing the Issuer sold (i) an aggregate amount of 47,717,087 shares of the Issuer's common stock and (ii) pre-funded warrants to purchase up to an aggregate amount of 9,332,000 shares of the Issuer's common stock. The Reporting Person acquired 21,241,163 shares of the Issuer's Common Stock in the Second Closing.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Charles Cherington

**Signature:** /s/ Charles Cherington

**Name/Title:** Charles Cherington

**Date:** 06/11/2025